Compare like-for-like revenue
The annual revenue series records AUD 42.43m for the period ended June 30, 2026. That is 15.2% above the same reporting basis a year earlier.
—
—
—
Little Green Pharma
—
—
Live Price
CIN RESEARCH · DATED EVIDENCE
Dated financial evidenceLittle Green Pharma: revenue expanded; follow the cash evidence.
The annual revenue series records AUD 42.43m for the period ended June 30, 2026. That is 15.2% above the same reporting basis a year earlier. Cash and operating cash flow are available on a matching dated basis.
Latest financial observation 2026-06-30Last reported price 2026-11-06Research checked 2026-11-07 13:30 UTC
The check time records a research refresh. Each financial figure and price keeps its own reporting date.
Revenue and profitability are separate
The matching annual net loss is AUD 1.41m. This is the reported result for 2026-06-30, not a future earnings estimate.
Put cash beside operating cash flow
Period-end cash was AUD 1.42m at 2026-06-30. The matching annual operating cash inflow was AUD 38,999. Later financing and cash movements are not established by this snapshot.
Follow the primary disclosures
The available record includes 5 primary disclosures. The latest is 2026-07-08. This is the available feed record, not a claim of complete filing coverage.
Reported financial evidence
| Measure | Reported value & unit | Period & interval | Evidence basis |
|---|---|---|---|
| Revenue | AUD 42.43mUnit: AUD | Annual period | Dated financial series |
| Cost of revenue | AUD 30.7mUnit: AUD | Annual period | Dated financial series |
| Gross profit | AUD 11.73mUnit: AUD | Annual period | Dated financial series |
| Operating income | AUD -1.96mUnit: AUD | Annual period | Dated financial series |
| EBITDA | AUD 1.85mUnit: AUD | Annual period | Dated financial series |
| Net income | AUD -1.41mUnit: AUD | Annual period | Dated financial series |
| Cash balance | AUD 1.42mUnit: AUD | Balance at period end | Dated financial series |
| Total assets | AUD 93.76mUnit: AUD | Balance at period end | Dated financial series |
| Total liabilities | AUD 10.72mUnit: AUD | Balance at period end | Dated financial series |
| Shareholders’ equity | AUD 83.03mUnit: AUD | Balance at period end | Dated financial series |
| Operating cash flow | AUD 38,999Unit: AUD | Annual period | Dated financial series |
| Free cash flow | AUD -790,000Unit: AUD | Annual period | Dated financial series |
A balance at period end is not income over a period. “Quarterly series” follows the available classification; the source disclosure establishes the actual reporting interval.
What changed against the prior year
Only the same measure, unit, reporting frequency and prior-year period end are compared. A reported change is not an investment rating.
Increased +15.2%
- 2025-06-30
- AUD 36,824,000
- 2026-06-30
- AUD 42,425,000
Increased +165.4%
- 2025-06-30
- AUD 11,565,000
- 2026-06-30
- AUD 30,696,000
Decreased -53.6%
- 2025-06-30
- AUD 25,259,000
- 2026-06-30
- AUD 11,729,000
Increased
- 2025-06-30
- AUD -4,049,000
- 2026-06-30
- AUD -1,959,000
Increased
- 2025-06-30
- AUD -684,000
- 2026-06-30
- AUD 1,849,000
Turned loss-making -142.4%
- 2025-06-30
- AUD 3,324,000
- 2026-06-30
- AUD -1,408,000
Decreased -40.2%
- 2025-06-30
- AUD 2,376,000
- 2026-06-30
- AUD 1,421,000
Decreased -2.5%
- 2025-06-30
- AUD 96,124,000
- 2026-06-30
- AUD 93,755,000
Decreased -3.5%
- 2025-06-30
- AUD 11,108,000
- 2026-06-30
- AUD 10,722,000
Decreased -2.3%
- 2025-06-30
- AUD 85,016,000
- 2026-06-30
- AUD 83,033,000
Increased
- 2025-06-30
- AUD -917,000
- 2026-06-30
- AUD 38,999
Increased
- 2025-06-30
- AUD -1,154,000
- 2026-06-30
- AUD -790,000
What to investigate next
- Resolve the conflicting financial observations against the primary report.
- Read the latest linked company disclosures and any reporting after the financial period.
- Check post-period financing, share issuance and changes in cash before drawing a current valuation conclusion.
Evidence boundaries
- Conflicting observations for the same concept, period and reporting basis are withheld.
- The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.
Primary company disclosures
Independent evidence summary. No broker consensus, price target or investment rating is manufactured. Research standards →
Price History · AUD
5 Years
Fundamentals
SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
CONTINUE YOUR RESEARCH